Another fully human anti-CD40 monoclonal recombinant IgG4, bleselumab, that failed to demonstrate efficacy in a clinical trial of 60 patients with moderate-to-severe psoriasis [111] was assessed alone or in combination with tacrolimus or mycophenolate mofetil, and appeared to provide encouraging benefits as an antirejection agent for improving renal allograft survival [112] and prolonging pancreatic islet allograft survival in cynomolgus monkeys [113]. The gene discussed is CD40; the disease is psoriasis.